CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


HP:0001297: StrokeHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (7)


Name (Synonyms) Correlation
drug264 COVID-19 swap test PCR Wiki 0.50
drug1514 allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC) Wiki 0.50
drug707 Intravenous saline injection (Placebo) Wiki 0.50
drug425 Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta Wiki 0.50
drug922 Observation Wiki 0.50
drug171 Best Practice Wiki 0.50
drug1402 Tocilizumab Wiki 0.11

Correlated MeSH Terms (12)


Name (Synonyms) Correlation
D020521 Stroke NIH 0.89
D009422 Nervous System Diseases NIH 0.50
D012640 Seizures NIH 0.50
D003072 Cognition Disorders NIH 0.50
D004827 Epilepsy NIH 0.50
D060825 Cognitive Dysfunction NIH 0.35
D007676 Kidney Failure, Chronic NIH 0.29
D003324 Coronary Artery Disease NIH 0.29
D029424 Pulmonary Disease, Chronic Obstructive NIH 0.25
D008173 Lung Diseases, Obstructive NIH 0.20
D009369 Neoplasms, NIH 0.14
D007239 Infection NIH 0.03

Correlated HPO Terms (6)


Name (Synonyms) Correlation
HP:0001268 Mental deterioration HPO 0.35
HP:0001250 Seizure HPO 0.35
HP:0001677 Coronary artery atherosclerosis HPO 0.29
HP:0006510 Chronic obstructive pulmonary disease HPO 0.29
HP:0006536 Obstructive lung disease HPO 0.22
HP:0002664 Neoplasm HPO 0.15

There are 4 clinical trials

Clinical Trials


1 Tociluzumab for Cytokine Release Syndrome With SARS-CoV-2: An Open-Labeled, Randomized Phase 3 Trial

This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.

NCT04361552 Cerebrovascular Accident Chronic Obstructive Pulmonary Disease Chronic Renal Failure Coronary Artery Disease Diabetes Mellitus Malignant Neoplasm SARS Coronavirus 2 Infection Other: Best Practice Biological: Tocilizumab
MeSH:Infection Lung Diseases, Obstructive Pulmonary Disease, Chronic Obstructive Stroke Kidney Failure, Chronic Coronary Artery Disease Neoplasms
HPO:Chronic obstructive pulmonary disease Coronary artery atherosclerosis Neoplasm Obstructive lung disease Stroke

Primary Outcomes

Description: The 7-day length of invasive MV for each arm will be estimated with 95% confidence intervals (CIs) using the exact binomial distribution. Their difference by the arms will be tested by Cochran-Mantel-Haenszel (CMH) test stratified by the age group and Sequential Organ Failure Assessment (SOFA) score at significance level of 0.05.

Measure: 7-day length of invasive mechanical ventilation (MV)

Time: Up to 7 days

Description: Defined as death within 30-day after randomization. The 30-day mortality rate for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

Measure: 30-day mortality rate

Time: Up to 30-day after randomization

Secondary Outcomes

Description: The rate of ICU transfer for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

Measure: Rate of intensive care (ICU) transfer

Time: Up to 2 years

Description: The rate of invasive mechanical ventilation for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

Measure: Rate of invasive mechanical ventilation

Time: Up to 2 years

Description: The rate of tracheostomy for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

Measure: Rate of tracheostomy

Time: Up to 2 years

Description: Will first be described by median and inter-quartile, and then compared between two arms by Wilcoxon Sum-Rank test

Measure: Length of ICU stay

Time: Up to 2 years

Measure: Length of hospital stay

Time: Up 2 years

2 Impact of th Covid-19 Epidemic on Acute Stroke Management

The Covid-19 pandemic is a pandemic of an emerging infectious disease, coronavirus 2019 (Covid-19), caused by the coronavirus SARS-CoV-2. It appears in November 2019 in the city of Wuhan, China, and spreads worldwide from February 2020. The first cases of infection in France were confirmed on 24 January 2020. As of April 14, 103,573 cases of infection were confirmed, 32,292 hospitalized cases, including 6,730 in intensive care, with 15,729 deaths recorded1. The most affected regions are Ile de France and the Grand Est (in particular the Haut-Rhin department). Containment of the entire French population was introduced on 17 March, with the aim of reducing the spread of the virus and relieving the burden on the health system, particularly the intensive care units. This unprecedented health crisis, as well as the social containment measures in themselves, has repercussions on other acute medical pthologies, not directly related to the viral infection. It appears that the number of patients treated for acute stroke has suddenly declined since the beginning of the epidemic. However, it is not clear whether it is the incidence of stroke that has declined or simply the proportion of patients presenting within the time frame that allows for treatment in the acute phase (by thrombolysis or thrombectomy).

NCT04370197 Stroke, Acute
MeSH:Stroke
HPO:Stroke

Primary Outcomes

Measure: Study of the effect of pandemic covid-19 on the management of stroke patients

Time: 1 month

3 Stroke Rehabilitation Outcome During COVID-19 Lockdown

COVID-19 has a big impact on individuals and society as a whole. Especially persons with (multiple) comorbidities such as stroke are affected. The impact of COVID-19 on stroke rehabilitation delivery and stroke patients' functioning is unclear.

NCT04373109 Stroke Rehabilitation COVID-19 Cohort Studies Behavioral: Observation
MeSH:Stroke
HPO:Stroke

Primary Outcomes

Description: Nature of rehabilitation therapy, and number and duration of rehabilitation therapy sessions

Measure: Rehabilitation data

Time: 3 month after start lockdown

Description: Patient-reported upper limb use in daily life

Measure: Motor Activity Log - 14 Item Version

Time: 3 month after start lockdown

Description: Patient-reported engagement in physical activity in daily life

Measure: International Physical Activity Questionnaire

Time: 3 month after start lockdown

Description: Patient-self-assessment comprising the following categories: 1) physical function, 2) anxiety, 3) depression, 4) fatigue, 5) sleep disturbance, 6) ability to participate in social roles and activities, 7) pain interference and 8) pain intensity

Measure: Patient-Reported Outcomes Measurement Information System - 29 Version

Time: 3 month after start lockdown

Secondary Outcomes

Description: Patient-reported global rating of physical activity engagement and upper limb use in daily life

Measure: Global Rating of Perceived Changes (physical activity engagement and upper limb use)

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

Description: Self-reported questionnaire regarding severity of fatigue and its influence on the performance of daily life activities

Measure: Fatigue Severity Scale

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

Description: Depression and anxiety

Measure: Hospital Anxiety and Depression Scale

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

Description: Assesses cognitive functions

Measure: Montreal Cognitive Assessment

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

Description: Classification regarding the ability to walk independently, with or without a walking aid and takes the type of walking surface into account

Measure: Functional Ambulation Categories

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

Description: Gait speed and cadence

Measure: Ten-Meter Walk Test

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

Description: Measures the ability of patients to make postural adjustments (e.g, move in bed), transfer (e.g. be-tween bed to chair), walk, and use stairs

Measure: Rivermead Mobility Index

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

Description: Self-reported measure in which patients rate how confident they are in maintaining balance when performing 16 daily life tasks

Measure: Activities-specific Balance Confidence Scale

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

Description: Upper and lower limb motor function

Measure: Fugl-Meyer Motor Assessment

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

Description: Upper limb capacity

Measure: Action Research Arm Test

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

Description: Global disability

Measure: modified Rankin Scale

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

Description: Neurological impairments

Measure: National Institutes of Health Stroke Scale

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 3 months after lockdown, 6 months after lockdown

Description: Nature of rehabilitation therapy, and number and duration of rehabilitation therapy sessions

Measure: Rehabilitation data

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdown

Description: Patient-reported upper limb use in daily life

Measure: Motor Activity Log - 14 Item Version

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdown

Description: Patient-reported engagement in physical activity in daily life

Measure: International Physical Activity Questionnaire

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdown

Description: Patient-self-assessment comprising the following categories: 1) physical function, 2) anxiety, 3) depression, 4) fatigue, 5) sleep disturbance, 6) ability to participate in social roles and activities, 7) pain interference and 8) pain intensity

Measure: Patient-Reported Outcomes Measurement Information System - 29 Version

Time: 4 weeks after lockdown ("extraordinary situation" as defined by the Swiss law), 6 months after lockdown

4 COVID-19 Prevalence, Morbidity and Long Term Cognitive Deficits in Consecutive Patients Presenting With Acute Neurological Symptoms

The purpose is to investigate the COVID-19 prevalence, associated morbidity and long-term cognitive deficits in consecutive patients presenting with acute neurological symptoms

NCT04377425 Neurological Diseases or Conditions Stroke, Acute Seizure Disorder Diagnostic Test: COVID-19 swap test PCR
MeSH:Stroke Seizures Epilepsy Cognition Disorders Cognitive Dysfunction Nervous System Diseases
HPO:Bilateral tonic-clonic seizure Cognitive impairment Focal sensory seizure Focal-onset seizure Generalized-onset seizure Mental deterioration Seizure Stroke

Primary Outcomes

Description: To investigate the prevalence of COVID-19 infections in consecutive patients with acute onset of neurological symptoms (with or without prior neurological disease)

Measure: Prevalence of COVID-19 infection in consecutive patients with neurological symptoms

Time: 6 months

Secondary Outcomes

Description: Three months cognitive function (Montreal Cognitive Assessment) of COVID-19 positive patients compared to COVID-19 negative patients

Measure: Three months cognitive function of COVID-19 positive patients

Time: 3 months

Description: Characterization of the neurological symptoms in neurological COVID-19 positive patients (exploratory endpoint)

Measure: Clinical presentation of neurological symptoms in COVID-19 positive patients

Time: 6 months

Description: Prevalence of pre-symptomatic and asymptomatic COVID-19pos in acutely admitted patients with a primary complaint of neurological symptoms.

Measure: Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients

Time: 6 months

Description: Prevalence of anosmia in COVID-19pos patients compared to COVID-19neg patients

Measure: Anosmia in COVID-19 positive patients

Time: 6 months

Description: Neuro-specific and inflammatory blood- and cerebrospinal fluid markers in COVID-19 positive patients compared to COVID-19 negative matched controls

Measure: Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection

Time: 24 months

Description: Functional and immunologic plasma assays will be employed to analyze proteins and pathways in coagulation and fibrinolysis

Measure: Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients

Time: 24 months


HPO Nodes